EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
A Randomized Phase II Study of Gefitinib Alone Versus Gefitinib Plus Thalidomide for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations
Sponsor: Fujian Cancer Hospital
A PHASE2 clinical study on Chemotherapy Effect and NSCLC Stage IV, this trial is ongoing. The trial is conducted by Fujian Cancer Hospital and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2020 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fujian Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .